Northern Trust Corp Buys 264,430 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Northern Trust Corp boosted its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 30.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,147,271 shares of the medical research company's stock after purchasing an additional 264,430 shares during the quarter. Northern Trust Corp owned approximately 0.62% of Exact Sciences worth $64,465,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Asset Planning Inc bought a new position in shares of Exact Sciences during the fourth quarter worth about $40,000. AlphaQuest LLC increased its stake in shares of Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after purchasing an additional 913 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of Exact Sciences during the fourth quarter valued at approximately $66,000. Ostrum Asset Management grew its holdings in Exact Sciences by 28.4% in the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock worth $134,000 after buying an additional 527 shares in the last quarter. Finally, Kieckhefer Group LLC acquired a new stake in Exact Sciences in the fourth quarter worth about $188,000. Institutional investors own 88.82% of the company's stock.

Wall Street Analysts Forecast Growth

EXAS has been the subject of a number of research reports. Guggenheim restated a "buy" rating and set a $60.00 target price on shares of Exact Sciences in a report on Friday, April 11th. Barclays upped their price target on Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. Royal Bank of Canada increased their target price on Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Bank of America lowered their price target on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Finally, Piper Sandler reduced their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Trading Up 1.3%

NASDAQ:EXAS traded up $0.68 on Monday, hitting $52.31. 237,726 shares of the stock were exchanged, compared to its average volume of 2,591,180. The company's 50-day moving average price is $45.52 and its 200 day moving average price is $52.59. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83. The stock has a market capitalization of $9.87 billion, a price-to-earnings ratio of -9.40 and a beta of 0.92. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. During the same quarter last year, the firm earned ($0.60) EPS. Exact Sciences's revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.